BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ti L, Kaplan K, Hayashi K, Suwannawong P, Wood E, Kerr T. Low rates of hepatitis C testing among people who inject drugs in Thailand: implications for peer-based interventions. J Public Health (Oxf). 2013;35:578-584. [PMID: 23335599 DOI: 10.1093/pubmed/fds105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Iakunchykova O, Meteliuk A, Zelenev A, Mazhnaya A, Tracy M, Altice FL. Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine. Int J Drug Policy 2018;57:11-7. [PMID: 29655101 DOI: 10.1016/j.drugpo.2018.03.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
2 Anagnostou O, Fotiou A, Kanavou E, Antaraki A, Terzidou M, Richardson C, Kafetzopoulos E; Drug Related Infectious Diseases (DRID) Medical Doctors Group of OKANA. Factors associated with HCV test uptake in heroin users entering substitution treatment in Greece. HIV Med 2018;19 Suppl 1:34-9. [PMID: 29488704 DOI: 10.1111/hiv.12589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Chang J, Shelly S, Busz M, Stoicescu C, Iryawan AR, Madybaeva D, de Boer Y, Guise A. Peer driven or driven peers? A rapid review of peer involvement of people who use drugs in HIV and harm reduction services in low- and middle-income countries. Harm Reduct J 2021;18:15. [PMID: 33536033 DOI: 10.1186/s12954-021-00461-z] [Reference Citation Analysis]
4 Prouté M, Le Coeur S, Tiv MH, Dub T, Jongpaijitsakul P, Ratnamhin A, Angkurawaranon C, Aramrattana A, Lallemant M. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs. BMC Public Health 2020;20:1450. [PMID: 32972359 DOI: 10.1186/s12889-020-09549-w] [Reference Citation Analysis]
5 Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, Londeix P, Forette C, Momenghalibaf A, Verster A, Swan T. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. Int J Drug Policy 2015;26:1088-93. [PMID: 26074094 DOI: 10.1016/j.drugpo.2015.05.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
6 Phisalprapa P, Tanwandee T, Neo BL, Singh S. Knowledge, attitude, and behaviors toward liver health and viral hepatitis-related liver diseases in Thailand. Medicine (Baltimore) 2021;100:e28308. [PMID: 34941122 DOI: 10.1097/MD.0000000000028308] [Reference Citation Analysis]
7 Marshall Z, Dechman MK, Minichiello A, Alcock L, Harris GE. Peering into the literature: A systematic review of the roles of people who inject drugs in harm reduction initiatives. Drug Alcohol Depend 2015;151:1-14. [PMID: 25891234 DOI: 10.1016/j.drugalcdep.2015.03.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 9.7] [Reference Citation Analysis]
8 Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T, Larney S, Hickman M, Vickerman P, French C, Butler K, Gibbs D, Valerio H, Read P, Dore GJ, Hajarizadeh B. Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. Clin Infect Dis 2021;73:e107-18. [PMID: 32447375 DOI: 10.1093/cid/ciaa612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol 2014; 20(36): 12722-12733 [PMID: 25278674 DOI: 10.3748/wjg.v20.i36.12722] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
10 Thinh VT, Phuong DT, Hoa VD, Giang LM. Reported Low Uptake of HCV Testing among People Who Inject Drugs in Urban Vietnam. Biomed Res Int 2020;2020:3701379. [PMID: 33274205 DOI: 10.1155/2020/3701379] [Reference Citation Analysis]
11 Karimi SE, Bayani A, Higgs P, Bayat AH, Hemmat M, Ahounbar E, Armoon B, Fakhri Y. Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis. Subst Abuse Treat Prev Policy 2020;15:64. [PMID: 32831107 DOI: 10.1186/s13011-020-00306-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ali S, Ur-Rehman T, Ali M, Haque S, Rasheed F, Lougher E, Nawaz MS, Paudyal V. Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme. Int J Clin Pharm 2021;43:958-68. [PMID: 33247820 DOI: 10.1007/s11096-020-01202-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Arain A, De Sousa J, Corten K, Verrando R, Thijs H, Mathei C, Buntinx F, Robaeys G. Pilot Study: Combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs. J Subst Abuse Treat 2016;67:44-9. [PMID: 27296661 DOI: 10.1016/j.jsat.2016.04.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]